Polysaccharide Composition for Connective Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating and repairing connective tissue injuries, such as tendons and ligaments, face challenges including excessive platelet activation leading to inflammation, scarring, and complications like thrombosis and restenosis, with existing treatments often requiring high doses of polysaccharides that can cause bleeding or renal issues, and lacking effective solutions for vascular restenosis and non-elastic scarring.
Innovation Solution
A synergistic combination of a glycosaminoglycan, a neutral polysaccharide, and an isomaltose oligomer in an aqueous solution is used to attenuate platelet hyperactivation, comprising hyaluronan and dextran, which reduces platelet activation and subsequent pathophysiological sequelae, while allowing for lower doses and safer administration, thereby enhancing connective tissue repair without fibrosis or scarring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of polysaccharides are used to treat connective tissue injuries, then healing effectiveness is improved, but bleeding and renal issues occur
Solution Approach 1:
The patent combines three different polysaccharides (hyaluronan, dextran, and isomaltose oligomer) in specific ratios to create a composite composition. This composite approach allows the treatment to achieve effective healing while reducing the toxic effects associated with high doses of single polysaccharides, as each component contributes different beneficial properties and they work synergistically together.
Solution Approach 2:
The patent specifies precise concentration ranges for each polysaccharide component (hyaluronan: 0.01-10%, dextran: 1-20%, isomaltose oligomer: 0.1-5%) to optimize both therapeutic effectiveness and safety. By controlling these parameters within defined ranges, the composition achieves effective connective tissue repair while minimizing harmful side effects like bleeding and renal issues.
2Reliability
If platelet activation is suppressed to reduce inflammation and scarring, then connective tissue repair is improved, but thrombosis and restenosis risks increase
Solution Approach 1:
The patent creates a composition with non-uniform properties by combining polysaccharides with different molecular weights and functional characteristics. Hyaluronan (high molecular weight) provides lubrication and anti-inflammatory effects locally at the injury site, while dextran and isomaltose oligomer (lower molecular weights) modulate platelet activation. This local quality differentiation allows selective suppression of harmful platelet activation without causing systemic thrombosis.
Solution Approach 2:
The polysaccharide composition acts as an intermediary substance that mediates between platelet activation and connective tissue repair. The specific combination of hyaluronan, dextran, and isomaltose oligomer creates a balanced environment that modulates platelet function to reduce inflammation and scarring while maintaining adequate thrombotic protection, thereby preventing both excessive scarring and thrombosis.
3Reliability
If immobilization is used to protect freshly sutured tendons, then healing is protected, but adhesion formation and loss of range of motion occur
Solution Approach 1:
The patent applies the polysaccharide composition preliminarily to the tendon injury site before the healing process begins. The composition creates a protective lubricating layer and modulates the inflammatory response in advance, which prevents adhesion formation during subsequent movement. This preliminary action allows the tendon to heal while maintaining range of motion, eliminating the need for prolonged immobilization.
4Strength
If bone-tendon-bone autograft is used for ACL reconstruction, then structural support is improved, but donor site morbidity and loss of mechanoreceptive capabilities occur
Solution Approach 1:
The patent extracts and eliminates the need for bone-tendon-bone autograft by using the polysaccharide composition to directly treat and repair the ACL injury. This extraction approach removes the harmful side effects of autografting (donor site morbidity and loss of mechanoreceptive capabilities) while still achieving the necessary structural support through enhanced natural healing processes facilitated by the composition.
Data Source
AI summary
A composition capable of attenuating platelet hyperactivation and associated methods for administering the same to a subject, the composition comprising an aqueous solution containing from about 0.1% to about 7.0% by weight of a glycosaminoglycan and from about 1.0% to about 32% by weight of a neutral polysaccharide.